Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hanger, Inc. stock logo
HNGR
Hanger
$18.72
$18.70
$13.42
$22.67
$732.38M1.28356,429 shsN/A
IMAC Holdings, Inc. stock logo
IMAC
IMAC
$0.04
-7.9%
$0.04
$0.75
$1.65
$1.09M-0.88708,132 shs2,517 shs
Envista Holdings Co. stock logo
NVST
Envista
$18.87
-1.9%
$16.95
$14.22
$23.00
$3.20B0.992.56 million shs1.37 million shs
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$32.80
+1.7%
$32.81
$26.74
$46.00
$2.52B1.09557,023 shs1.06 million shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hanger, Inc. stock logo
HNGR
Hanger
0.00%0.00%0.00%0.00%0.00%
IMAC Holdings, Inc. stock logo
IMAC
IMAC
-7.87%+2.50%+29.75%-92.68%-98.37%
Envista Holdings Co. stock logo
NVST
Envista
+0.33%+2.32%+3.48%+18.51%+5.93%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
+0.31%+5.91%-10.01%-8.30%-15.02%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Hanger, Inc. stock logo
HNGR
Hanger
N/AN/AN/AN/AN/AN/AN/AN/A
IMAC Holdings, Inc. stock logo
IMAC
IMAC
N/AN/AN/AN/AN/AN/AN/AN/A
Envista Holdings Co. stock logo
NVST
Envista
3.4078 of 5 stars
2.22.00.03.82.60.01.9
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
3.6791 of 5 stars
4.54.00.00.02.82.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Hanger, Inc. stock logo
HNGR
Hanger
0.00
N/AN/AN/A
IMAC Holdings, Inc. stock logo
IMAC
IMAC
0.00
N/AN/AN/A
Envista Holdings Co. stock logo
NVST
Envista
2.33
Hold$20.237.21% Upside
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
3.00
Buy$54.8267.13% Upside

Current Analyst Ratings Breakdown

Latest HNGR, IMAC, NVST, and XENE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2025
Envista Holdings Co. stock logo
NVST
Envista
Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
5/27/2025
Envista Holdings Co. stock logo
NVST
Envista
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Outperform$21.00 ➝ $23.00
5/14/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$55.00
5/13/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$50.00 ➝ $47.00
5/13/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$58.00 ➝ $55.00
5/13/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$53.00 ➝ $53.00
5/13/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$55.00 ➝ $55.00
5/13/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$60.00 ➝ $55.00
5/7/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$55.00
5/5/2025
Envista Holdings Co. stock logo
NVST
Envista
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$21.00 ➝ $18.00
5/5/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Hanger, Inc. stock logo
HNGR
Hanger
$1.12B0.65$1.88 per share9.98$2.85 per share6.57
IMAC Holdings, Inc. stock logo
IMAC
IMAC
$15.22M0.07N/AN/A$0.69 per share0.06
Envista Holdings Co. stock logo
NVST
Envista
$2.50B1.28$1.46 per share12.91$17.04 per share1.11
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$7.50M335.58N/AN/A$14.18 per share2.31
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Hanger, Inc. stock logo
HNGR
Hanger
$41.98M$0.9519.7115.60N/A3.17%35.72%4.00%N/A
IMAC Holdings, Inc. stock logo
IMAC
IMAC
-$10.54MN/A0.00N/AN/A-75.40%-52.17%-34.51%N/A
Envista Holdings Co. stock logo
NVST
Envista
-$1.12B-$6.53N/A15.601.27-44.56%3.86%2.21%8/6/2025 (Estimated)
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$182.39M-$3.23N/AN/AN/AN/A-24.69%-23.68%8/6/2025 (Estimated)

Latest HNGR, IMAC, NVST, and XENE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$0.90-$0.83+$0.07-$0.83$1.64 million$7.50 million
5/1/2025Q1 2025
Envista Holdings Co. stock logo
NVST
Envista
$0.20$0.24+$0.04$0.10$608.17 million$616.90 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Hanger, Inc. stock logo
HNGR
Hanger
N/AN/AN/AN/AN/A
IMAC Holdings, Inc. stock logo
IMAC
IMAC
N/AN/AN/AN/AN/A
Envista Holdings Co. stock logo
NVST
Envista
N/AN/AN/AN/AN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Hanger, Inc. stock logo
HNGR
Hanger
3.71
1.23
0.85
IMAC Holdings, Inc. stock logo
IMAC
IMAC
0.01
1.27
1.27
Envista Holdings Co. stock logo
NVST
Envista
0.44
2.04
1.76
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/A
22.21
22.21

Institutional Ownership

CompanyInstitutional Ownership
Hanger, Inc. stock logo
HNGR
Hanger
79.17%
IMAC Holdings, Inc. stock logo
IMAC
IMAC
24.27%
Envista Holdings Co. stock logo
NVST
Envista
N/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
95.45%

Insider Ownership

CompanyInsider Ownership
Hanger, Inc. stock logo
HNGR
Hanger
4.36%
IMAC Holdings, Inc. stock logo
IMAC
IMAC
10.00%
Envista Holdings Co. stock logo
NVST
Envista
1.30%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
5.52%
CompanyEmployeesShares OutstandingFree FloatOptionable
Hanger, Inc. stock logo
HNGR
Hanger
5,20039.12 million37.42 millionOptionable
IMAC Holdings, Inc. stock logo
IMAC
IMAC
10626.49 million23.84 millionNot Optionable
Envista Holdings Co. stock logo
NVST
Envista
12,700169.49 million169.95 millionOptionable
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
21076.73 million72.03 millionOptionable

Recent News About These Companies

Brokers Set Expectations for XENE FY2026 Earnings
Xenon Pharmaceuticals Inc. stock logo
Cantor Fitzgerald Estimates XENE FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Hanger stock logo

Hanger NYSE:HNGR

Hanger, Inc. provides orthotic and prosthetic (O&P) services in the United States. It operates in two segments, Patient Care and Products & Services. The Patient Care segment owns and operates Hanger clinic, which specializes in the design, fabrication, and delivery of custom O&P devices through patient care clinics and satellite locations; and offers payor network contracting services to other O&P providers. The Products & Services segment engages in the distribution of various O&P parts, componentry, and devices to independent O&P providers; development of specialized rehabilitation technologies; and provision of evidence-based clinical programs for post-acute rehabilitation to patients at approximately 4,000 skilled nursing and post-acute providers. This segment also manufactures and sells therapeutic footwear for diabetic patients in the podiatric market. As of December 31, 2021, the company operated approximately 760 patient care clinics and 115 satellite locations in 47 states and the District of Columbia. It also distributes O&P devices and components, manages O&P networks, and provides therapeutic solutions to patients and businesses in acute, post-acute, and clinic settings. The company was formerly known as Hanger Orthopedic Group, Inc. and changed its name to Hanger, Inc. in June 2012. Hanger, Inc. was founded in 1861 and is headquartered in Austin, Texas.

IMAC stock logo

IMAC NASDAQ:IMAC

$0.04 0.00 (-7.87%)
As of 06/10/2025

IMAC Holdings, Inc. owns, manages, and subleases a chain of innovative medical advancements and care regeneration centers in the United States. The company's outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains. It also provides physical therapy and spinal decompression, and chiropractic manipulation. The company owns or manages 15 outpatient medical clinics in Kentucky, Missouri, Tennessee, Illinois, Louisiana, and Florida. IMAC Holdings, Inc. was founded in 2000 and is headquartered in Brentwood, Tennessee.

Envista stock logo

Envista NYSE:NVST

$18.87 -0.36 (-1.87%)
As of 03:59 PM Eastern

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

Xenon Pharmaceuticals stock logo

Xenon Pharmaceuticals NASDAQ:XENE

$32.80 +0.54 (+1.67%)
As of 04:00 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.